NASDAQ:NLNKNewLink Genetics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.48 +0.33 (+2.18 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$13.75Now: $15.48▼$16.0950-Day Range$0.89MA: $9.07▼$14.1052-Week Range$0.82Now: $15.48▼$3.60Volume104,770 shsAverage Volume547,540 shsMarket Capitalization$577.84 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for NewLink Genetics. Previous Next 2.8 Community Rank Outperform VotesNewLink Genetics has received 385 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNewLink Genetics has received 307 “underperform” votes. (Add your “underperform” vote.)Community SentimentNewLink Genetics has received 55.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote “Outperform” if you believe NLNK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNewLink Genetics does not currently pay a dividend.Dividend GrowthNewLink Genetics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewLink Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.70% of the stock of NewLink Genetics is held by insiders.Percentage Held by InstitutionsOnly 32.32% of the stock of NewLink Genetics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NewLink Genetics is -13.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewLink Genetics is -13.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewLink Genetics has a P/B Ratio of 7.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NLNK Previous Symbol CUSIP65151110 CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$940,000.00 Price / Sales614.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book7.34Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-42,990,000.00 Net Margins-4,592.84% Return on Equity-41.50% Return on Assets-33.95%Miscellaneous Employees55 Outstanding Shares37,328,000Market Cap$577.84 million Next Earnings DateN/A OptionableOptionable Receive NLNK News and Ratings via Email Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter. NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of NewLink Genetics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for NewLink Genetics. How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) announced its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative return on equity of 41.50%. View NewLink Genetics' earnings history. Has NewLink Genetics been receiving favorable news coverage? News headlines about NLNK stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NewLink Genetics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about NewLink Genetics. Who are some of NewLink Genetics' key competitors? Some companies that are related to NewLink Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Opko Health (OPK), SunPower (SPWR), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Cara Therapeutics (CARA), Alibaba Group (BABA) and Celldex Therapeutics (CLDX). Who are NewLink Genetics' key executives? NewLink Genetics' management team includes the following people: Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)Mr. Brian Wiley, Chief Commercial Officer (Age 51)Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64) What is NewLink Genetics' stock symbol? NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK." What is NewLink Genetics' stock price today? One share of NLNK stock can currently be purchased for approximately $15.48. How big of a company is NewLink Genetics? NewLink Genetics has a market capitalization of $577.84 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe. What is NewLink Genetics' official website? The official website for NewLink Genetics is www.newlinkgenetics.com. How can I contact NewLink Genetics? NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
